Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - imunoglobulin, normalni humani, za intravensku primjenu - rastvor za infuziju - 50g/l

Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

glaxosmithkline d.o.o.sarajevo - пропорциональному protiv difterije, hemofilus utjecaj b, pertusisa, poliomijelitisa, tetanusa, hepatitisa b - prašak i suspenzija za suspenziju za injekciju - ≥ 30 i.j./0.5 ml+ ≥ 40 i.j./0.5 ml+ 25 µg/0.5 ml+ 25 µg/0.5 ml+ 8 µg/0.5 ml+ 10 µg/0.5 ml+ 40 agu/0.5 ml+ 8 agu/0.5 ml+ 32 agu/0 - 0,5 ml suspenzije za injekciju (1 doza) sadrži: ne manje od 30 i.j. toksoid difterije, adsorbovani ne manje od 40 i.j. toksoid tetanusa, adsorbovani 25 mcg pertusis toksoid, adsorbovani 25 mcg filamentozni hemaglutinin, adsorbovani 8 mcg pertaktin, adsorbovani 10 mcg površinski antigen hepatitis b virusa 40 dantigen jedinica polio virus, inaktivirani, tip 1 8 dantigen jedinica polio virus, inaktivirani, tip 2 32 dantigen jedinica polio virus, in aktivirani, tip 3 10 mcg polisaharid hemofilusa tip b (konjugovan na toksoid tetanusa), adsorbovani

Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

roche d.o.o.roche ltd. - okrelizumab - koncentrat za otopinu za infuziju - 300 mg/10 ml - 1 bočica sa 10 ml koncetrata za otopinu za infuziju sadrži: 300 mg okrelizumaba (30 mg/1 ml)

Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

evropa lijek pharma d.o.o. - пропорциональному protiv difterije, hemofilus utjecaj b, pertusisa, poliomijelitisa, tetanusa, hepatitisa b - prašak i suspenzija za suspenziju za injekciju - ≥ 30 i.j./0.5 ml+ ≥ 40 i.j./0.5 ml+ 25 µg/0.5 ml+ 25 µg/0.5 ml+ 8 µg/0.5 ml+ 10 µg/0.5 ml+ 40 agu/0.5 ml+ 8 agu/0.5 ml+ 32 agu/0 - 0,5 ml suspenzije za injekciju (1 doza) sadrži: ne manje od 30 i.j. toksoid difterije, adsorbovani ne manje od 40 i.j. toksoid tetanusa, adsorbovani 25 mcg pertusis toksoid, adsorbovani 25 mcg filamentozni hemaglutinin, adsorbovani 8 mcg pertaktin, adsorbovani 10 mcg površinski antigen hepatitis b virusa 40 dantigen jedinica polio virus, inaktivirani, tip 1 8 dantigen jedinica polio virus, inaktivirani, tip 2 32 dantigen jedinica polio virus, in aktivirani, tip 3 10 mcg polisaharid hemofilusa tip b (konjugovan na toksoid tetanusa), adsorbovani

Κροατία - Κροατικά - HALMED (Agencija za lijekove i medicinske proizvode)

octapharma (ip) sprl, allee de la recherche 65, anderlecht, belgija - imunoglobulin normalni, ljudski, intravenski - otopina za infuziju - 100 mg/ml - urbroj: 1 ml otopine za infuziju sadrži 100 mg imunoglobulina normalnog, ljudskog (čistoća od najmanje 95 % igg)

Κροατία - Κροατικά - HALMED (Agencija za lijekove i medicinske proizvode)

jana pharm d.o.o., lopašićeva 6, zagreb, hrvatska - imunoglobulin normalni, ljudski, intravenski - otopina za infuziju - 50 mg/ml - urbroj: jedan ml otopine za infuziju sadrži 50 mg imunoglobulina normalnog, ljudskog, što odgovara ukupnom sadržaju proteina od čega je najmanje 95% ljudski imunoglobulin g

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

glaxosmithkline d.o.o.sarajevo - virus rota drugarima, živi, atenuisani - oralna suspenzija - ≥ 10 megaccid50/1.5 ml - 1,5 ml oralne suspenzije (1 doza) sadrži: humani rotavirus, živi, atenuirani, soj rix4414 ne manje od 10 na šestu ccid50

Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amicus pharma d.o.o. - пропорциональному protiv difterije, hemofilus utjecaj b, pertusisa, poliomijelitisa, tetanusa, hepatitisa b - suspenzija za injekciju - ≥ 20 i.j./0.5 ml+ ≥ 40 i.j./0.5 ml+ 25 µg/0.5 ml+ 25 µg/0.5 ml+ 40 d'ag'u/0.5 ml+ 8 d'ag'u/0.5 ml+ 32 d'ag'u/0.5 ml+ 10 µg/0.5 m - 0,5 ml suspenzije za injekciju sadrži: toksoid difterije ne manje od 20 iu toksoid tetanusa ne manje od 40 iu bordetella pertussis antigeni pertussis toksoid 25 mikrograma filamentozni hemaglutinin 25 mikrograma virus poliomijelitisa (inaktivirani) tip 1 (mahoney) 40 d antigen jedinica tip 2 (mef1) 8 d antigen jedinica tip 3 (saukett) 32 d antigen jedinica površinski antigen virusa hepatitisa b 10 mikrograma haemophilus influenzae tip b polisaharid 12 mikrograma (poliribozilribitol fosfat) konjugiran na protein tetanusa (2236 mikrograma)

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).